Evolus, Inc. (EOLS) income statement
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$7.07+0.38 (+5.68%)
Close on Nov 18, 2026Market cap $466.98MP/E –Yield –
Evolus, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 66.7%
- Operating margin
- -5.9%
- Net margin
- -10.8%
- Return on equity, FY2025
- 587.4%
Financial strength
- Current ratio
- 1.70
- Debt to equity
- -5.07
- Debt to assets
- 63.2%
- Cash to current liabilities
- 45.8%
Valuation
- P/E ratio
- –
- Price to sales
- 1.48
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?